TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17270058
Drug: OROS hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS hydromorphone 32 mg
Study: 17270058
Drug: OROS hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS hydromorphone 64 mg
Study: 17270058
Drug: OROS hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS hydromorphone (all doses)
Study: 15475600
Drug: Sodium-lactate infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium-lactate infusion (LC) during exercise
Study: 15475600
Drug: Control (Con)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (Con) with isotonic, isovolumetric saline infusion during exercise
Study: 8585710
Drug: Nursing intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nursing intervention to instill hope; duration: 4 weeks; specific details on dosage not available.
Study: 15954973
Drug: Cimetidine 4
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 4 mg kg(‐1) preoperatively
Study: 15954973
Drug: Cimetidine 4
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 4 mg kg(‐1) postoperatively
Study: 12964500
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day zinc supplementation
Study: 1929105
Drug: Daily corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily corticosteroid therapy (group A) for an additional year
Study: 1929105
Drug: Alternate-day corticosteroid
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day corticosteroid therapy (group B) for an additional year
Study: 1929105
Drug: Switch from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch from daily to alternate-day corticosteroid therapy after one year (for group A)
Study: 1578306
Drug: Alternate-day corticosteroid
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day corticosteroid therapy
Study: 7059094
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion after acid infusion
Study: 7059094
Drug: Placebo-antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-antacid
Study: 30682680
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment with lorazepam
Study: 26626539
Drug: Bobath neurodevelopmental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bobath neurodevelopmental treatment (NDT) (n = 22)
Study: 25146692
Drug: DTG 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTG 50 mg q24h for 5 days followed by DTG 50 mg and EFV 600 mg q24h for 14 days
Study: 25146692
Drug: DTG 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTG 50 mg q24h for 5 days followed by TPV/r 500/200 mg q12h for 7 days and then DTG 50 mg q24h and TPV/r 500/200 mg q12h for a further 5 days
Study: 22614936
Drug: PM (physician
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM (physician management) with weekly buprenorphine dispensing
Study: 22614936
Drug: PM+DOT/CBT (physician
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM+DOT/CBT (physician management and directly observed, thrice-weekly buprenorphine with cognitive-behavioral therapy)
Study: 19066301
Drug: DHEA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (50 mg/d for 3 months)
Study: 17968836
Drug: Antiviral drugs
Normalized name: antiviral drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral drugs (adamantanes and neuraminidase inhibitors)
Study: 17968836
Drug: Nonpharmacologic interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonpharmacologic interventions (e.g., handwashing, contact isolation)
Study: 16036028
Drug: b‐adrenergic receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: b‐adrenergic receptor antagonists (b‐blockers)
Study: 11575415
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection on median nerve stimulation (group 1)
Study: 11575415
Drug: Double injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double injection divided between median and radial nerves (group 2)
Study: 2254515
Drug: Family-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based behavioral treatment targeting child and parent behavior
Study: 2254515
Drug: Family-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based behavioral treatment
Study: 6929102
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of doxycycline infused i.v. during the operation and daily for 4 days postoperatively
Study: 6929102
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of doxycycline infused i.v. during the operation, plus 200 mg instilled into the peritoneal cavity at the completion of the operation
Study: 31274211
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg vitamin D3
Study: 26070652
Drug: Half-dose L-T4
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Half-dose L-T4 treatment for 5 weeks (HD group)
Study: 26070652
Drug: Conventional L-T4
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conventional L-T4 withdrawal (TW group)
Study: 26070652
Drug: Half-dose L-T4
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Half-dose L-T4 treatment (HD group)
Study: 25002722
Drug: Weekly topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly topotecan 4 mg/m² IV with ziv-aflibercept 6 mg/kg IV every 21 days
Study: 25002722
Drug: Weekly topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly topotecan 4 mg/m² IV
Study: 22332815
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received only oral and written instructions on Kegel exercises after catheter removal.
Study: 19295468
Drug: Diaphragm/gel provision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaphragm/gel provision
Study: 17713339
Drug: Individually designed
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually designed patient-centered preventive program including counseling, toothbrushes, fluoride toothpaste, fluoride and xylitol lozenges, and fluoride/chlorhexidine varnish applications.
Study: 11448848
Drug: Water immersion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water immersion (WI) with sustained angiotensin-converting enzyme inhibitor therapy in HF patients
Study: 375408
Drug: Levamisole at
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole at 3 mg/kg daily for 8 days
Study: 375408
Drug: Mebendazole at
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mebendazole at 6 mg/kg daily for 10 days following 8 days of levamisole
Study: 375408
Drug: Diethylcarbamazine (DEC)
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine (DEC) at 6 mg/kg daily for 12 days
Study: 11176742
Drug: Chelation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chelation therapy for patients with high-normal BLB
Study: 7535192
Drug: Drugs inhibiting
Normalized name: C1-inhibiting factor
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs inhibiting nitric oxide (NO)
Study: 3377974
Drug: Monochloroacetic acid
Normalized name: MONOCHLOROACETIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monochloroacetic acid crystals and 60% salicylic acid ointment
Study: 28059619
Drug: Oral rotavirus
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rotavirus vaccine (RV) before injection
Study: 28059619
Drug: Oral rotavirus
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rotavirus vaccine (RV) after injection
Study: 15320956
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg escitalopram daily
Study: 15320956
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg citalopram daily
Study: 15320956
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg escitalopram after 8 weeks
Study: 11055323
Drug: 3-acetyl-7-oxo-DHEA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-acetyl-7-oxo-DHEA (50 mg/d for 7 days, 100 mg/d for 7 days, 200 mg/d for 28 days)
Study: 11055323
Drug: 3-acetyl-7-oxo-DHEA (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-acetyl-7-oxo-DHEA (200 mg/d for 28 days)
Study: 11354235
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of sertraline
Study: 11282810
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of paroxetine
Study: 8302414
Drug: CSA liquid
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSA liquid (mean dose 312 mg/day)
Study: 8302414
Drug: CSA capsules
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSA capsules (mean dose 312 mg/day)
Study: 8302414
Drug: CSA capsules
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSA capsules
Study: 3532669
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy with dietary advice
Study: 30541041
Drug: Intra-articular corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular corticosteroid (triamcinolone 20 mg)
Study: 27118785
Drug: Laninamivir octanoate
Normalized name: Laninamivir octanoate
DrugBank: Laninamivir octanoate (DB11888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laninamivir octanoate 40 mg single administration (LO‐40SD)
Study: 27118785
Drug: Laninamivir octanoate
Normalized name: Laninamivir octanoate
DrugBank: Laninamivir octanoate (DB11888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laninamivir octanoate 20 mg once daily for 2 days (LO‐20TD)
Study: 22513048
Drug: ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (8 mg/d; group O, n=10)
Study: 22513048
Drug: metoclopramide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoclopramide (30 mg/d; group M, n=10)
Study: 20381932
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (8 sessions, 60 min each over 8 weeks)
Study: 15572587
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine (HiDAC) alone, 3 courses
Study: 15572587
Drug: Multiagent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiagent chemotherapy regimen (1 course of HiDAC, 1 course with etoposide and cyclophosphamide, 1 course with diaziquone and mitoxantrone)
Study: 15572587
Drug: Both regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both regimens (HiDAC and multiagent chemotherapy)
Study: 22920577
Drug: Dexamethasone treatment
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone treatment (intramuscularly)
Study: 21060024
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy followed by surgery
Study: 16182827
Drug: Tacrolimus (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (initial oral dose 0.2 mg/kg) with MMF (2 to 3 g per day) and rATG induction therapy (4 mg/kg for 4 days)
Study: 16182827
Drug: Cyclosporine‐microemulsion (ME)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine‐microemulsion (ME) (initial daily oral dose 7 mg/kg) with MMF (2 to 3 g per day) and rATG induction therapy (1.25 mg/kg for 4 days)
Study: 12559940
Drug: Inogatran (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inogatran (a direct thrombin inhibitor)
Study: 12559940
Drug: High fibrinogen
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fibrinogen level (pre-treatment top tertile)
Study: 29255272
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg every other day, once a morning
Study: 23701115
Drug: Spontaneous ventilation
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spontaneous ventilation (SV) using dexmedetomidine (4 μg∙kg(‐1)) and topical lidocaine (3‐5 mg∙kg(‐1))
Study: 23701115
Drug: Manual jet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual jet ventilation (MJV) with fentanyl (2 μg∙kg(‐1)), propofol (3‐5 mg∙kg(‐1)), and succinylcholine (1 mg∙kg(‐1))
Study: 19214115
Drug: Diaphragm +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaphragm + gel + condoms
Study: 11436970
Drug: Pharmacotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy plus immunotherapy (IT) in tablets
Study: 25894106
Drug: Pharmacotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy alone (Control)
Study: 8290411
Drug: Hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25 mg) + Amiloride (2.5 mg)
Study: 8290411
Drug: Hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25 mg) + Triamterene (50 mg)
Study: 30550209
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with nasal corticosteroids (budesonide) and nasal antihistamine (azelastine) for 8 weeks
Study: 27138024
Drug: Aclidinium bromide/formoterol
Normalized name: Aclidinium Bromide/Formoterol Fumarate 400 MCG/1 ACTUATION-12 MCG/1 ACTUATION Inhalation Aerosol Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) 400/12 μg
Study: 27138024
Drug: Formoterol fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol fumarate 12 μg
Study: 25137221
Drug: 30 min/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 min/day walking prescription
Study: 25137221
Drug: 60 min/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 min/day walking prescription
Study: 25137221
Drug: 90 min/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 min/day walking prescription
Study: 1602034
Drug: Metronidazole, 250
Normalized name: MetroNIDAZOLE, 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole, 250 mg 3 x a day for 1 week
Study: 3912193
Drug: Cyclacillin with
Normalized name: cyclacillin
DrugBank: Cyclacillin (DB01000)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclacillin with Amoxicillin
Study: 20472815
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (mean treatment duration of 25.6 months)
Study: 12915698
Drug: Buformine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buformine treatment (n=10)
Study: 10591092
Drug: Preoperative diuretics
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative diuretics
Study: 8713688
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg) +/− Indapamide (2.5 mg)
Study: 30804274
Drug: Oral steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroids for 6 months
Study: 29069003
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 250 mL 20% mannitol and 1 L 0.9% saline orally at 05:00 hours on the day of the procedure.
Study: 29069003
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: Same preparation as Group A, taken at 20:00 on the day before, and at 05:00 on the day of CE; in addition, 20 mL oral simethicone taken 30 minutes before CE.
Study: 29069003
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: Identical to Group B, except patients fasted for 3 days and took 3 g senna orally 3 times daily before CE.
Study: 17062760
Drug: Single-dose bexarotene
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single-dose bexarotene (400 mg/m2)
Study: 15313870
Drug: Pollen blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pollen blocker cream applied 4 times daily for 9 days
Study: 15313870
Drug: Carboxymethylcellulose in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboxymethylcellulose in gel (placebo) applied 4 times daily for 9 days
Study: 11181682
Drug: Oral docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral docetaxel 75 mg/m(2) with CsA 15 mg/kg
Study: 11181682
Drug: Oral docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral docetaxel 75 mg/m(2) without CsA
Study: 11181682
Drug: Intravenous docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous docetaxel 100 mg/m(2)
Study: 9037321
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor treatment (fosinopril)
Study: 8316680
Drug: Thioridazine 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine 1.25 mg/kg/day
Study: 8316680
Drug: Thioridazine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine 2.5 mg/kg/day
Study: 3528988
Drug: Morphine (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (n = 9)
Study: 31612329
Drug: Preoperative neoadjuvant
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative neoadjuvant chemotherapy
Study: 31612329
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of immune checkpoint inhibitors to cytotoxic chemotherapy
Study: 18688284
Drug: AEB071 (PKC
Approvals — FDA: no, EMA: no, PMDA: no
Description: AEB071 (PKC inhibitor), administered as single and multiple ascending oral doses to patients with psoriasis.
Study: 18688284
Drug: AEB071 (PKC
Approvals — FDA: no, EMA: no, PMDA: no
Description: AEB071 (PKC inhibitor), administered as single doses to healthy volunteers.
Study: 18688284
Drug: AEB071 (PKC
Approvals — FDA: no, EMA: no, PMDA: no
Description: AEB071 (PKC inhibitor), administered to patients with psoriasis.
Study: 12872392
Drug: Fuzheng Yiliu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzheng Yiliu Granule (FYG) in addition to conventional chemotherapy
Study: 10344610
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of amphotericin B per liter of sterile water as continuous irrigation for 72 hours at the rate of 42 mL/hr
Study: 10344610
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of amphotericin B per liter of sterile water as continuous irrigation for 72 hours at the rate of 42 mL/hr
Study: 1722769
Drug: Bleomycin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin treatment (15 mg by continuous infusion two times a week during 5 weeks)
Study: 1722769
Drug: Classical radiation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical radiation treatment with telecobalt‐therapy 50 Gy/25 fractions plus 32 Gy/4 fractions (Cathetron)
Study: 31854054
Drug: Intensive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive group (individualized nutritional treatment)
Study: 21605175
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application of betamethasone valerate 0.1% corticosteroid cream
Study: 21605175
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily application of betamethasone valerate 0.1% corticosteroid cream
Study: 21605175
Drug: Urea-containing moisturizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea-containing moisturizer (substituted for corticosteroid cream in the morning)
Study: 19016342
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg BH(4)/kg body weight
Study: 19016342
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg BH(4)/kg body weight
Study: 19016342
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg BH(4)/kg body weight
Study: 15028243
Drug: [(11)C]L‐deprenyl (DEP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: [(11)C]L‐deprenyl (DEP)
Study: 11597936
Drug: Intensive lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive lipid-lowering therapy (niacin 2.5 g/d, lovastatin 40 mg/d, colestipol 20 g/d) for 10 years
Study: 2586436
Drug: OK-432 intratumoral
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: OK-432 intratumoral injection (group A)
Study: 195411
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (COMB)
Study: 195411
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (BACO)
Study: 16414235
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m² and Docetaxel 35 mg/m²
Study: 3718600
Drug: Diphenhydramine (DPH)
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenhydramine (DPH) preparations A (tablet) and B (buffered solution) containing 50 mg DPH-HCl
Study: 3718600
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation C containing 31 mg DPH-HCl and 23 mg 8-chlorotheophylline
Study: 3718600
Drug: Combination with
Normalized name: Iron in combination with folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination with 8-chlorotheophylline
Study: 2431015
Drug: Lindane 1%
Normalized name: LINDANE 1% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lindane 1% lotion
Study: 21597409
Drug: Piracetam 12
Normalized name: piracetam 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam 12 g
Study: 9129038
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose cytosine arabinoside and daunomycin + rhG‐CSF
Study: 7948961
Drug: C2T (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: C2T (2 g ceftazidime every 8 h plus 5 mg/kg/day tobramycin)